ClinicalTrials.gg
CompletedNCT01128569Updated Jan 18, 2017Results posted

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

A Phase 2 interventional study of Fluticasone Furoate and FF/Vilanterol (VI; GW642444M) in Asthma, sponsored by GlaxoSmithKline. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
24th of 40
52 · median 102
Started
2010
with 6 others
Phase 2
12 of 40
none open now
Registered
12th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 24th largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 12th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • mild asthma
  • allergen challenge
  • early asthmatic response
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within the range 18.5-35.0 kilograms/metre2 (kg/m2).
  • Females of non-child bearing potential.
  • Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation
  • Pre-bronchodilator >70% of predicted at screening
  • Subjects who are current non-smokers
  • Methacholine challenge PC20 \< 8 mg/mL at screening
  • Screening allergen challenge demonstrates that the subject experiences an early asthmatic response

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities
  • Subject is hypertensive at screening
  • Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.
  • History of life-threatening asthma
  • Symptomatic with hay fever at screening or predicted to have symptomatic hayfever
  • Unable to abstain from short acting beta agonists
  • Unable to abstain from antihistamines
  • Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication
  • The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months
  • undergoing allergen desensitisation therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Inhaler

    Drug: Placebo

  • Active comparator
    inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)

    ICS/LABA inhaler

    Drug: FF/Vilanterol (VI; GW642444M)

  • Active comparator
    ICS

    ICS inhaler

    Drug: Fluticasone Furoate

Interventions

  • FF

    Also known as: FF

  • DrugFF/Vilanterol (VI; GW642444M)

    Drug page: Vilanterol

    FF/VI

    Also known as: FF/VI

  • DrugPlacebo

    Placebo Inhaler

06

What researchers measure

Primary outcomes

  1. Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.

    Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)

Secondary outcomes

  1. Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.

    Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)

  2. Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value

    Time frame: Baseline and Day 29 of each treatment period (up to Study Day 197)

  3. Number of Participants With Treatment-emergent Adverse Events (AEs)

    The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.

    Time frame: From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)

07

Results

Posted Sep 11, 2013

Participant flow

Participants were screened within 42 days of the first dose, conducted over 2 days (not consecutive days). During this time, a methacholine challenge and an allergen challenge test were performed. Participants meeting all inclusion criteria and none of the exclusion criteria were randomized to 3 study treatment periods, each lasting 28 days.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneSequence 1: Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: Placebo, FF/VI 100/25 µg, FF 100 µgSequence 3: FF 100 µg, FF/VI 100/25 µg, PlaceboSequence 4: FF 100 µg, Placebo, FF/VI 100/25 µgSequence 5: FF/VI 100/25 µg, Placebo, FF 100 µgSequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo
Started989899
Completed989899
Not completed000000
Washout Period 1
Participant flow — Washout Period 1
MilestoneSequence 1: Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: Placebo, FF/VI 100/25 µg, FF 100 µgSequence 3: FF 100 µg, FF/VI 100/25 µg, PlaceboSequence 4: FF 100 µg, Placebo, FF/VI 100/25 µgSequence 5: FF/VI 100/25 µg, Placebo, FF 100 µgSequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo
Started989899
Completed988899
Not completed001000
Withdrew: Adverse event001000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneSequence 1: Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: Placebo, FF/VI 100/25 µg, FF 100 µgSequence 3: FF 100 µg, FF/VI 100/25 µg, PlaceboSequence 4: FF 100 µg, Placebo, FF/VI 100/25 µgSequence 5: FF/VI 100/25 µg, Placebo, FF 100 µgSequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo
Started988899
Completed978899
Not completed010000
Withdrew: Withdrawal by subject010000
Washout Period 2
Participant flow — Washout Period 2
MilestoneSequence 1: Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: Placebo, FF/VI 100/25 µg, FF 100 µgSequence 3: FF 100 µg, FF/VI 100/25 µg, PlaceboSequence 4: FF 100 µg, Placebo, FF/VI 100/25 µgSequence 5: FF/VI 100/25 µg, Placebo, FF 100 µgSequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo
Started978899
Completed978899
Not completed000000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneSequence 1: Placebo, FF 100 µg, FF/VI 100/25 µgSequence 2: Placebo, FF/VI 100/25 µg, FF 100 µgSequence 3: FF 100 µg, FF/VI 100/25 µg, PlaceboSequence 4: FF 100 µg, Placebo, FF/VI 100/25 µgSequence 5: FF/VI 100/25 µg, Placebo, FF 100 µgSequence 6: FF/VI 100/25 µg, FF 100 µg, Placebo
Started978899
Completed978899
Not completed000000

Outcome measures

PrimaryWeighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants (par.) were exposed to an allergen (administered by inhalation) 22-23 hours after dosing on Day 28. FEV1 was measured 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours post-allergen challenge on Day 29. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1 were recorded at 1-minute intervals, and the best was taken as the post-saline value. The FEV1 weighted mean was derived by calculating the area under the curve, and then dividing the value by the relevant time interval. Weighted mean change from Baseline is calculated as the weighted mean FEV1 value on Day 29 minus the Baseline value. The Baseline FEV1 value was the post-saline value on Day 29.

Time frame:
Baseline and Day 29 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Weighted Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Between 0-2 Hours, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period-0.372 ± 0.0557-0.210 ± 0.0549-0.227 ± 0.0550
Statistical analysis
  • Placebo vs FF 100 µg OD · Mean difference (final values): 0.162 · 95% CI 0.087 to 0.237
  • Placebo vs FF/VI 100/25 µg OD · Mean difference (final values): 0.145 · 95% CI 0.069 to 0.222
  • FF 100 µg OD vs FF/VI 100/25 µg OD · Mean difference (final values): -0.017 · 95% CI -0.091 to 0.057
SecondaryMaximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes (min) after inhalation of saline, 3 single measurements of FEV1were recorded at 1-min intervals, and the best was taken as the post-saline value. The maximum change (i.e., drop in FEV1) from post-saline Baseline (BL) is defined by ordering all of the change from BL values for the 5 min, 10 min, 15 min, 20 min, 30 min, and 45 min and the 1 hour, 1.5 hours, and 2 hours post-allergen challenge and selecting the largest change (i.e., drop in FEV1) from the BL value. If there were no negative change values, indicating a worse FEV1 value as compared to the BL value, the smallest change in FEV1, indicating an improvement from the BL value, was selected. The BL FEV1 value was the post-saline value on Day 29.

Time frame:
Baseline and Day 29 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Percent change
Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
Percent changePlaceboFF 100 µg ODFF/VI 100/25 µg OD
Maximum Percent Decrease From Baseline in FEV1 Between 0 2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period-24.991 ± 2.0736-14.040 ± 2.0435-13.206 ± 2.0491
SecondaryMinimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 22-23 hours after dosing on Day 28. Immediately prior to the exposure of allergen and starting at 2 minutes after inhalation of saline, 3 single measurements of FEV1were recorded at 1-minute intervals, and the best was taken as the post-saline value. The minimum FEV1 over 0-2 hours post-allergen challenge (PAC) (minimum early asthmatic response) was the minimum value of all of the PAC time points up to and including 2 hours PAC (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, and 45 min and 1 hour, 1.5 hours, and 2 hours). Change from Baseline was calculated using the post-saline FEV1 on Day 29 as Baseline. Minimum FEV1 absolute change from Baseline between 0-2 hour, following the 22-23 hour post-treatment allergen challenge was calculated as the minimum change value on Day 29 minus the Baseline value

Time frame:
Baseline and Day 29 of each treatment period (up to Study Day 197)
Reported as:
Least squares mean · Liters
Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period
LitersPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Minimum FEV1 Absolute Change From Baseline Between 0-2 Hour, Following the 22-23 Hour Post-treatment Allergen Challenge on Day 29 of Each Treatment Period-0.809 ± 0.0775-0.479 ± 0.0765-0.478 ± 0.0767
SecondaryNumber of Participants With Treatment-emergent Adverse Events (AEs)

The number of participants with treatment-emergent AEs was measured. A treatment-emergent adverse event is defined as any event not present prior to the initiation of the treatments, or any event already present that worsens in either intensity of frequency following exposure to the treatments.

Time frame:
From the start of study medication until Follow-up/Early Withdrawal (up to 197 days)
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (AEs)
participantsPlaceboFF 100 µg ODFF/VI 100/25 µg OD
Number of Participants With Treatment-emergent Adverse Events (AEs)202218

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up/Early Withdrawal (up to 197 days).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/51 (0%)15/51 (29.4%)
FF 100 µg OD—0/51 (0%)18/51 (35.3%)
FF/VI 100/25 µg OD—0/51 (0%)11/51 (21.6%)
Most frequent other events
Most frequent other events
EventPlaceboFF 100 µg ODFF/VI 100/25 µg OD
HeadacheNervous system disorders9/5111/515/51
CoughRespiratory, thoracic and mediastinal disorders1/513/510/51
NasopharyngitisInfections and infestations3/512/510/51
Chest discomfortGeneral disorders3/510/510/51
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/512/512/51
DysphoniaRespiratory, thoracic and mediastinal disorders0/512/512/51
Mouth ulcerationGastrointestinal disorders0/512/512/51
NauseaGastrointestinal disorders2/512/510/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences
Mean35.4 ± 8.63
Gender
Gender(Participants)Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences
Female18
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo, FF 100 µg OD, FF/VI 100/25 µg OD in 1 of 6 Sequences
White - White/Caucasian/European Heritage48
African American/African Heritage2
Asian - South East Asian Heritage1
Mixed Race1
08

Study locations

4 sites
  • GSK Investigational Site
    Berlin, 14050, Germany
  • GSK Investigational Site
    Wellington, 6021, New Zealand
  • GSK Investigational Site
    London, NW10 7EW, United Kingdom
  • GSK Investigational Site
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Publications

  • Oliver A, Quinn D, Goldfrad C, van Hecke B, Ayer J, Boyce M. Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial. Clin Transl Allergy. 2012 Jun 27;2(1):11. doi: 10.1186/2045-7022-2-11. PubMed 22738148 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 11 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
May 24, 2010
Start
Jan 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results delay requested
Mar 15, 2012
Results first posted
Sep 11, 2013
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01128569
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 24, 2010
Start date
Jan 2010
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Sep 11, 2013
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion